Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Venous Thromboembolism 3Venous Thrombosis 1Thromboembolism 1Pancreatic Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Pancreatic Ductal 1Abdominal Neoplasms 1

Interventions

Gemcitabine 13130-nm albumin-bound paclitaxel 10Albumin-Bound Paclitaxel 7Oxaliplatin 4Leucovorin 4Fluorouracil 4Carboplatin 4Paclitaxel 3Cisplatin 3Cetuximab 3Bevacizumab 3pembrolizumab 2napabucasin 2Pemetrexed 2PEGPH20 2MK-4721 2tremelimumab 1relacorilant 1irinotecan sucrosofate 1ensituximab 1durvalumab 1cc-486 1Taxes 1Lead 1Irinotecan 1Enoxaparin 1EC regimen 1Dexamethasone 1CP protocol 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Pancreatic Ductal × Enoxaparin × Clear all
NCT01839487 2020-07-20

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Halozyme Therapeutics

Phase 2 Completed
279 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡